Korro Bio, Inc. (KRRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Korro Bio, Inc. (KRRO) has a cash flow conversion efficiency ratio of -0.134x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.07 Million) by net assets ($119.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Korro Bio, Inc. net asset quality index to measure how much of total assets are equity-financed.
Korro Bio, Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Korro Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Korro Bio, Inc. (KRRO) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Korro Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Korro Bio, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ellington Residential Mortgage
NYSE:EARN
|
0.029x |
|
PBA Holdings Bhd
KLSE:5041
|
0.032x |
|
A Paradise Acquisition Corp.
NYSE:APAD
|
-0.001x |
|
Oriola-KD Oyj B
HE:OKDBV
|
0.229x |
|
Elixir Energy Ltd
AU:EXR
|
-0.036x |
|
ES Cube Co. Ltd
KQ:050120
|
-0.025x |
|
Photocure
OL:PHO
|
0.054x |
|
Dongkook Ind
KO:001620
|
0.135x |
Annual Cash Flow Conversion Efficiency for Korro Bio, Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Korro Bio, Inc. from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Korro Bio, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $51.44 Million | $-78.56 Million | -1.527x | -307.82% |
| 2024-12-31 | $160.41 Million | $-60.07 Million | -0.374x | +5.43% |
| 2023-12-31 | $169.91 Million | $-67.28 Million | -0.396x | -173.10% |
| 2022-12-31 | $-99.03 Million | $-53.65 Million | 0.542x | +320.81% |
| 2021-12-31 | $130.82 Million | $-32.09 Million | -0.245x | -4.50% |
| 2020-12-31 | $192.49 Million | $-45.19 Million | -0.235x | -214.83% |
| 2019-12-31 | $167.36 Million | $34.22 Million | 0.204x | -46.55% |
| 2018-12-31 | $-44.51 Million | $-17.02 Million | 0.382x | -22.42% |
| 2017-12-31 | $-29.64 Million | $-14.61 Million | 0.493x | -- |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate … Read more